Favipiravir 200 mg) at a price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir was originally developed by Japan's Fujifilm Holdings Corp under the brand name Avigan for treating influenza.Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease, the pharma company said.Commenting on the launch, Kirti Ganorkar, CEO of India Business of Sun Pharma, said, “With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals.